V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10405611 | 10057034 | null | null | null | 2017-02-12 | 2017-03-19 | Trial Unspecified | N | null | ELOQUENT2 TRIAL | 100690085 |
| 10405823 | 10057035 | null | null | null | null | 2020-04-06 | Obinutuzumab | 02 | null | LANREOTIDE | 101016992 |
| 10405960 | 10057036 | null | null | null | 2016-06-04 | 2018-05-20 | THALIDOMIDE | 02 | null | BORTEZOMIB + MELPHALAN | 101636181 |
| 10405992 | 10057037 | 1.57 | 74.65 | null | 2018-09-25 | 2018-10-01 | Capecitabine + Mitomycin | null | null | OSIMERTINIB | 101791626 |
| 10406018 | 10057038 | null | null | null | 2017-08-19 | 2019-03-06 | null | null | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100181934 |
| 10406034 | 10057039 | 1.6 | 84.7 | null | 2021-03-10 | 2021-07-07 | Bexarotene | 02 | null | BRENTUXIMAB | 100435760 |
| 10406162 | 10057040 | null | null | 03 | 2019-06-11 | 2019-08-27 | Bevacizumab+Carbo+Pacliaxel | 02 | N | DOCETAXEL + TRASTUZUMAB | 100415871 |
| 10406306 | 10057041 | 1.86 | 80.6 | 03 | 2019-11-06 | 2019-11-22 | CarboPEC-Taxol | 02 | N | SORAFENIB | 101444411 |
| 10406321 | 10057042 | 1.85 | 73.95 | null | null | 2018-07-08 | LENVATINIB | 02 | null | DASATINIB | 101299104 |
| 10406542 | 10057044 | 1.77 | 76.7 | null | 2018-10-20 | 2019-08-26 | Docetaxel + nintedanib | 02 | null | CLADRIBINE | 100408144 |
| 10407064 | 10057045 | 1.66 | 72.2 | null | null | 2019-11-26 | ABEMACICLIB + FULVESTRANT | 02 | null | ERIBULIN | 100531099 |
| 10407673 | 10057046 | null | null | Palliative (P) | 2017-08-11 | 2017-08-18 | Ipilimumab | 02 | N | OLAPARIB | 101636867 |
| 10407830 | 10057047 | 1.63 | 65 | null | 2017-05-19 | 2017-05-19 | CAV | null | null | BCG | 100920085 |
| 10408403 | 10057049 | null | null | null | 2019-12-05 | 2019-12-18 | GDP | 02 | null | LORLATINIB | 101029680 |
| 10408442 | 10057051 | 0 | 78.4 | Curative (C) | 2020-07-17 | 2020-07-17 | PETREA TRIAL | 02 | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100540929 |
| 10408496 | 10057052 | null | null | Adjuvant (A) | 2019-08-02 | 2019-08-02 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | N | CHLORAMBUCIL + RITUXIMAB | 101250182 |
| 10408511 | 10057053 | null | 52.4 | Palliative (P) | null | 2016-12-26 | CAPECITABINE + TEMOZOLOMIDE | 02 | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + PROCARBAZINE + VINCRISTINE | 101107522 |
| 10408584 | 10057054 | 1.72 | 79.2 | Palliative (P) | 2019-04-20 | 2019-06-02 | FLUOROURACIL + OXALIPLATIN + Trastuzumab | Y | N | CAPECITABINE + CARBOPLATIN | 101185546 |
| 10408658 | 10057055 | null | null | null | 2019-07-14 | 2019-08-20 | null | null | null | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101204875 |
| 10408909 | 10057056 | 1.68 | 86 | null | null | 2018-07-05 | null | 02 | null | BEVACIZUMAB | 101262958 |
| 10408967 | 10057057 | null | null | null | null | 2018-09-12 | Busulfan Oral | 02 | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 100864006 |
| 10409217 | 10057058 | null | null | Adjuvant (A) | 2017-06-10 | 2017-06-10 | BLEOMYCIN | 02 | N | BLEOMYCIN | 101473163 |
| 10409363 | 10057059 | null | null | 03 | 2019-06-22 | 2019-06-29 | BEAM | N | N | CISPLATIN + CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101422272 |
| 10409542 | 10057061 | null | null | Curative (C) | null | 2020-08-08 | R GCVP | null | N | TRASTUZUMAB EMTANSINE | 100586671 |
| 10409639 | 10057062 | null | null | Palliative (P) | 2016-10-31 | 2016-11-10 | R GCVP | N | N | FLUOROURACIL + MITOMYCIN | 101660794 |
| 10409940 | 10057063 | 1.73 | 0 | Curative (C) | null | 2021-05-12 | Ipilimumab | 02 | N | BOSUTINIB | 101609885 |
| 10410025 | 10057064 | 1.72 | 85.8 | Palliative (P) | 2019-05-20 | 2019-06-03 | Bevacizumab 7.5mg/kg | 02 | N | FLAIR TRIAL | 101209874 |
| 10410164 | 10057065 | null | null | null | 2017-07-16 | 2018-03-02 | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | N | null | RUCAPARIB | 100279961 |
| 10410368 | 10057066 | null | null | 03 | null | 2017-01-20 | RCEOP | 02 | N | CAPECITABINE + TRASTUZUMAB | 100153451 |
| 10410404 | 10057067 | 1.66 | 81.5 | 03 | 2021-05-24 | 2021-05-24 | CAR-T Tecartus + Cyclophosphamide + Fludarabine | 02 | 2 | BEVACIZUMAB | 101660431 |
| 10410422 | 10057068 | 1.56 | 84.5 | Adjuvant (A) | 2019-07-31 | 2020-04-11 | null | 01 | null | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101161472 |
| 10410612 | 10057069 | null | null | null | null | 2019-07-04 | BLEOMYCIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + GEMCITABINE + RITUXIMAB + VINBLASTINE | 02 | null | ABEMACICLIB | 101686065 |
| 10410684 | 10057070 | 1.52 | 70 | null | 2018-03-15 | 2018-03-18 | Bendamustine + Obinutuzumab | N | null | FULVESTRANT + RIBOCICLIB | 100401278 |
| 10410827 | 10057071 | null | null | null | null | 2019-07-27 | FLUOROURACIL + OXALIPLATIN + PANITUMUMAB | null | null | CISPLATIN + CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + THALIDOMIDE | 101432799 |
| 10410951 | 10057073 | 1.5 | 0 | null | 2019-07-06 | 2019-08-18 | VISMODEGIB | 02 | N | VISMODEGIB | 100557383 |
| 10410967 | 10057074 | null | null | Palliative (P) | 2015-01-14 | 2015-12-26 | GEMCITABINE + RITUXIMAB | 02 | null | ISATUXIMAB + POMALIDOMIDE | 101676702 |
| 10411042 | 10057076 | 1.6 | 77 | null | 2018-09-23 | 2018-10-01 | Doxorubicin + Olaratumab | 02 | null | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | 101059147 |
| 10411344 | 10057077 | 1.66 | 80 | null | 2019-09-18 | 2019-10-14 | Capecitabine + Cisplatin | null | null | FULVESTRANT + PALBOCICLIB | 101332368 |
| 10411609 | 10057078 | null | null | Curative (C) | null | 2018-07-21 | Panitumumab | 02 | N | ANAGRELIDE | 101515451 |
| 10411732 | 10057079 | 1.81 | 59.1 | 03 | 2017-11-25 | 2018-07-03 | CHLVPP | N | N | BEVACIZUMAB | 100791723 |
| 10411899 | 10057080 | 1.47 | 67.8 | Palliative (P) | 2018-03-24 | 2018-05-27 | null | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100710407 |
| 10411976 | 10057081 | null | null | Palliative (P) | null | 2018-08-05 | ANAGRELIDE | null | null | OXALIPLATIN + MDG | 101809948 |
| 10411984 | 10057082 | null | null | null | 2016-10-30 | 2016-11-05 | AXITINIB | 02 | null | CHLORAMBUCIL + RITUXIMAB | 101140401 |
| 10412003 | 10057083 | null | null | null | 2019-10-07 | 2019-10-08 | CYCLOPHOSPHAMIDE + RITUXIMAB | 01 | null | TRASTUZUMAB EMTANSINE | 100384497 |
| 10412204 | 10057084 | null | null | Curative (C) | 2020-04-21 | 2020-04-21 | LENALIDOMIDE + RITUXIMAB | 02 | N | BENDAMUSTINE + CYTARABINE + RITUXIMAB | 100986138 |
| 10412256 | 10057087 | 1.56 | 52.25 | Curative (C) | null | 2019-12-02 | FLAG + Idarubicin | 02 | N | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 101807502 |
| 10412385 | 10057088 | 1.57 | 101.6 | null | 2017-12-02 | 2017-12-07 | EVEROLIMUS | 02 | null | ABEMACICLIB + FULVESTRANT | 100680448 |
| 10412394 | 10057089 | 1.68 | 84 | Adjuvant (A) | 2017-12-19 | 2017-12-21 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | ANAGRELIDE | 100190269 |
| 10412516 | 10057090 | null | null | null | 2019-10-08 | 2019-10-08 | MPT | 02 | null | CYTARABINE HIGH DOSE | 101339286 |
| 10412690 | 10057092 | 1.63 | 91.6 | null | 2021-09-22 | 2022-01-01 | IRINOTECAN + MDG + PANITUMUMAB | null | null | IRINOTECAN + MDG | 100651306 |